Our Pricing

How Long Has Mounjaro Been Around? Complete UK Timeline

If you're wondering how long has Mounjaro been around, you're not alone — this dual-action weight loss treatment has a relatively recent but impressive regulatory history. Mounjaro (tirzepatide) received FDA approval in May 2022 for type 2 diabetes, followed by MHRA licensing in the UK in September 2022, with weight management approval granted in November 2023 [1]. At Cured Pharmacy, we've dispensed Mounjaro to thousands of UK patients since it became available, offering transparent pricing from £135.00 with free clinical assessment by our UK-registered prescribers.

How Long Has Mounjaro Been Around: The Global Timeline

Understanding how long has Mounjaro been around requires looking at both its development history and regulatory milestones. Eli Lilly began developing tirzepatide in the early 2010s, with the first human trials commencing in 2014 [1]. The pivotal SURPASS clinical trial programme, which enrolled over 10,000 participants across multiple studies, ran from 2018 through 2021.

The United States FDA granted approval for Mounjaro (tirzepatide) on 13 May 2022 for the treatment of type 2 diabetes under the brand name Mounjaro [2]. This made it the first dual GIP/GLP-1 receptor agonist licensed anywhere in the world. Just four months later, on 14 September 2022, the UK's MHRA followed suit, licensing Mounjaro for type 2 diabetes management in adults [1].

The weight management indication came later — the FDA approved tirzepatide for chronic weight management under the brand name Zepbound in November 2023, whilst the MHRA granted UK approval for Mounjaro's weight loss indication on 7 November 2023 [3]. This means Mounjaro has been around for weight loss treatment in the UK for just over one year, though many prescribers were using it off-label for weight management during 2023 under specialist supervision.

The Science Behind Mounjaro: Why Timing Matters

Whilst how long has Mounjaro been around might seem like a short period compared to older weight loss medications, its clinical evidence base is remarkably robust. The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, demonstrated that patients achieved an average weight reduction of 22.5% over 72 weeks on the highest dose — results that surpassed any previous pharmacological intervention for obesity [3].

Mounjaro works by activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously [1]. This dual mechanism distinguishes it from single-pathway treatments like Wegovy (semaglutide) and Saxenda (liraglutide), which only target GLP-1 receptors. The combined action appears to produce greater effects on appetite regulation, glucose metabolism, and energy expenditure.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), notes that despite Mounjaro's relatively recent arrival, the underlying science builds on decades of incretin research. The GLP-1 pathway has been studied since the 1980s, and the addition of GIP receptor activation represents a logical evolution rather than an entirely novel approach [2].

Clinical Trial Timeline

The SURPASS programme for type 2 diabetes ran from 2018 to 2021, enrolling participants across five major trials (SURPASS-1 through SURPASS-5). The SURMOUNT programme for weight management followed a similar structure from 2019 to 2022, with SURMOUNT-1 being the landmark study that demonstrated the 22.5% average weight reduction [3]. These extensive trials mean that whilst Mounjaro itself has only been around since 2022, we have robust safety and efficacy data spanning over four years of controlled observation.

How Long Has Mounjaro Been Around Compared to Other Treatments?

When considering how long has Mounjaro been around relative to alternative weight loss medications, context is essential. Orlistat, available as Xenical or Alli, received UK approval in 1998 — making it over 25 years old [4]. Saxenda (liraglutide) was licensed for weight management in the UK in 2015, whilst Wegovy (semaglutide) gained approval in September 2021 [5].

This means Mounjaro is the newest addition to the UK's prescription weight loss treatment landscape, having been around for just over two years since its initial MHRA approval and one year for the specific weight management indication. However, 'newer' doesn't mean 'less proven' — the clinical trial programme for tirzepatide actually involved more participants and longer follow-up periods than many older medications had at the time of their approval.

At Cured Pharmacy, we stock the full range of MHRA-licensed weight loss treatments, from established options like Orlistat (from £135.00) to the latest innovations. Our UK prescribers assess each patient individually to determine the most appropriate treatment, considering medical history, previous treatment responses, and personal preferences alongside the evidence base for each medication.

Regulatory Differences Across Markets

It's worth noting that how long has Mounjaro been around varies slightly by jurisdiction. Whilst the FDA and MHRA approvals came within months of each other in 2022, the European Medicines Agency (EMA) granted approval in September 2022, and other markets followed different timelines. The weight management indication also rolled out at different times — the US approval came first in November 2023, with the UK following the same month [3]. This staggered global rollout is typical for novel medications and reflects different regulatory processes rather than any concerns about safety or efficacy.

UK Availability and Supply: How Long Has Mounjaro Been Around in Pharmacies?

Understanding how long has Mounjaro been around also means looking at practical availability. Following MHRA approval in September 2022, Mounjaro pens began appearing in UK pharmacies in late 2022, though initial supplies were limited and primarily directed toward NHS diabetes services [1]. Private prescription availability expanded throughout 2023, particularly after the weight management indication was granted in November 2023.

Cured Pharmacy has stocked Mounjaro since early 2023, and we've seen demand increase substantially following the weight loss approval. All our Mounjaro stock is UK-licensed and sourced through legitimate pharmaceutical supply chains — we never dispense unlicensed or imported versions. Each prescription requires clinical assessment by our UK-registered prescribers, ensuring appropriate patient selection and monitoring.

Supply challenges have affected the UK market periodically since Mounjaro's launch, reflecting high global demand for GLP-1 receptor agonists. Eli Lilly has invested heavily in manufacturing capacity, and availability has improved significantly throughout 2024 [2]. At Cured Pharmacy, we maintain regular stock across all licensed doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg KwikPens), with transparent pricing from £135.00 and no hidden consultation fees.

What We've Learned Since Mounjaro Has Been Around

Although how long has Mounjaro been around might seem brief — just over two years since initial approval — the real-world experience has already taught us valuable lessons beyond the clinical trials. Post-marketing surveillance data from both the US and UK confirms the safety profile observed in trials, with gastrointestinal side effects (nausea, diarrhoea, constipation) being the most commonly reported [3].

We've also learned practical insights about administration and adherence. The once-weekly injection schedule appears to improve compliance compared to daily injections like Saxenda, and the KwikPen delivery device receives positive feedback from patients for its ease of use [1]. Dose escalation — starting at 2.5mg and gradually increasing every four weeks — helps minimise side effects whilst allowing the body to adapt to the medication.

Our clinical team at Cured Pharmacy has observed that patients who combine Mounjaro with structured lifestyle modifications tend to achieve better outcomes than those relying on medication alone. This aligns with the trial protocols, where all participants received dietary counselling and exercise guidance alongside tirzepatide [3]. We provide comprehensive patient information materials and ongoing prescriber support to optimise treatment success.

Long-Term Safety Considerations

One common question about how long has Mounjaro been around relates to long-term safety data. Whilst the medication itself has only been licensed since 2022, the SURPASS and SURMOUNT trials included follow-up periods of up to 72 weeks, and extension studies are ongoing [3]. The GLP-1 receptor agonist class as a whole has been studied for over 15 years, providing broader context for the safety profile. As with any medication, long-term real-world data will continue to accumulate, and regulatory bodies like the MHRA continuously monitor safety signals through pharmacovigilance programmes.

Getting Started with Mounjaro at Cured Pharmacy

Now that you understand how long has Mounjaro been around and its regulatory journey, you might be considering whether it's right for you. At Cured Pharmacy, the process begins with a free online consultation that takes under three minutes to complete. Our UK-registered prescribers review your medical history, current medications, and weight loss goals to determine if Mounjaro is clinically appropriate.

Mounjaro is typically prescribed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [5]. These criteria align with NICE guidance and MHRA licensing conditions. If Mounjaro isn't suitable, our prescribers can discuss alternatives including Wegovy (from £135.00), Saxenda (from £135.00), or Orlistat-based treatments.

Once approved, we dispense genuine UK-licensed Mounjaro KwikPens with discreet packaging and next-day delivery options. Your prescription includes clear administration instructions, and our pharmacy team remains available for ongoing support throughout your treatment. We also provide guidance on injection technique, storage requirements, and what to expect during the initial dose escalation phase. Pricing is transparent from the start at £135.00 with no hidden consultation charges or subscription fees.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2022). Mounjaro 2.5 mg solution for injection in pre-filled pen: UK Public Assessment Report. GOV.UK. https://www.gov.uk/government/publications/mounjaro-25-mg-solution-for-injection-in-pre-filled-pen
2. US Food and Drug Administration. (2022). FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes. FDA News Release. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. European Medicines Agency. (1998). Xenical: EPAR – Product Information. EMA. https://www.ema.europa.eu/en/medicines/human/EPAR/xenical
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to treatment, diet, and exercise. Mounjaro is a prescription-only medicine and may not be suitable for everyone.